Plain-English translation of NCT06475326 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Pancreatic Cancer research guide →Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether , a new immune-boosting medication, works better when combined with a chemotherapy regimen called NALIRIFOX for people with locally advanced pancreatic cancer that cannot currently be surgically removed. The goal is to shrink the tumors enough to make surgery possible, and to evaluate whether this combination is safe and effective.
Locally advanced pancreatic cancer is very difficult to treat because the tumors are too large or invasive to operate on when first diagnosed. This trial is exploring whether combining the medication with chemotherapy can shrink tumors enough to allow surgery, which offers patients a better chance at long-term survival.
You likely qualify if…
You likely don't qualify if…
You would receive the immune-boosting medication as an intravenous infusion once every four weeks, along with chemotherapy administered every two weeks in a repeating cycle. The combination aims to shrink your tumor over several months. Throughout the trial, you will have regular blood tests, imaging scans, and clinic visits to monitor how the cancer responds and check for any side effects. Depending on how well the treatment works, you may then be eligible for surgery or other follow-up treatments.
AI-generated summary from trial data · Jul 15, 2026 · Not medical advice
China